The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.
September 12th 2025
Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.
Clinical Overview: Cyletzo, a Biosimilar Version of Adalimumab
July 19th 2022Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Read More